Alexion Reports Third Quarter 2013 Results

25-10-2013 Business Wire HealthComments (0)

Alexion PharmaceuticalsPharmaceutical

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the three and nine months ended September 30, 2013. The Company reported net product sales of Soliris® (eculizumab) of $400.4 million in the third quarter of 2013, an increase of 36 percent from the same period in 2012. Revenue performance for the quarter reflected steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) globally, and an increasing number of

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top